The Long Non-coding RNA is Associated with and the Absence of FRA16D Breakage in Osteosarcoma Patients

Overview

Journal Oncotarget

Specialty Oncology

Date 2017 Nov 21

PMID 29152092

Citations 4

Authors

Valerie Brid OLeary

Doris Maugg

Jan Smida

Daniel Baumhoer

Michaela Nathrath

Saak Victor Ovsepian

Michael John Atkinson

Affiliations

Soon will be listed here.

Abstract

Breakage of the fragile site FRA16D disrupts the (WW Domain Containing Oxidoreductase) tumor suppressor gene in osteosarcoma. However, the frequency of breakage is not sufficient to explain the rate of loss in pathogenesis. The involvement of non-coding RNA transcripts is proposed due to their accumulation at fragile sites, where they are advocated to influence specific chromosomal regions associated with malignancy. The long ncRNA (promoter of antisense radiation-induced circulating long non-coding RNA) is transiently elevated in response to irradiation and influences epigenetic silencing modification within . It now emerges that elevated levels are significantly associated with FRA16D non-breakage in OS patients. Although not associated with overall survival, high levels were found to be significantly linked to metastasis free outcome. The transcription of both and are transiently responsive to exposure to low doses of radiation in osteosarcoma cell lines. Herein, a relationship between and transcription is suggested in human osteosarcoma cell lines representing alternative genetic backgrounds. over-expression ameliorated promoter activity in U2OS harboring FRA16D non-breakage. It can be concluded that the lncRNA influences the tumor suppressor and in the absence of FRA16D breakage, it is associated with OS metastasis-free survival.

Citing Articles

Epigenetic Changes Associated with Osteosarcoma: A Comprehensive Review.

Twenhafel L, Moreno D, Punt T, Kinney M, Ryznar R Cells. 2023; 12(12).

PMID: 37371065 PMC: 10297049. DOI: 10.3390/cells12121595.

All-Trans Retinoic Acid Fosters the Multifarious U87MG Cell Line as a Model of Glioblastoma.

Pokorna M, Hudec M, Jurickova I, Vacha M, Polivkova Z, Kutna V Brain Sci. 2021; 11(6).

PMID: 34207434 PMC: 8234004. DOI: 10.3390/brainsci11060812.

Long noncoding RNA DNAJC3-AS1 promotes osteosarcoma progression via its sense-cognate gene DNAJC3.

Liang R, Liu Z, Chen Z, Yang Y, Li Y, Cui Z Cancer Med. 2019; 8(2):761-772.

PMID: 30652414 PMC: 6382712. DOI: 10.1002/cam4.1955.

Abnormally expressed long non-coding RNAs in prognosis of Osteosarcoma: A systematic review and meta-analysis.

Chen D, Wang H, Zhang M, Jiang S, Zhou C, Fang B J Bone Oncol. 2018; 13:76-90.

PMID: 30591861 PMC: 6303364. DOI: 10.1016/j.jbo.2018.09.005.

References

Durkin S, Glover T . Chromosome fragile sites. Annu Rev Genet. 2007; 41:169-92. DOI: 10.1146/annurev.genet.41.042007.165900. View

Chang N, Hsu L, Lin Y, Lai F, Sheu H . WW domain-containing oxidoreductase: a candidate tumor suppressor. Trends Mol Med. 2006; 13(1):12-22. DOI: 10.1016/j.molmed.2006.11.006. View

Smith D, McAvoy S, Zhu Y, Perez D . Large common fragile site genes and cancer. Semin Cancer Biol. 2006; 17(1):31-41. DOI: 10.1016/j.semcancer.2006.10.003. View

Krummel K, Denison S, Calhoun E, Phillips L, Smith D . The common fragile site FRA16D and its associated gene WWOX are highly conserved in the mouse at Fra8E1. Genes Chromosomes Cancer. 2002; 34(2):154-67. DOI: 10.1002/gcc.10047. View

Kurek K, Del Mare S, Salah Z, Abdeen S, Sadiq H, Lee S . Frequent attenuation of the WWOX tumor suppressor in osteosarcoma is associated with increased tumorigenicity and aberrant RUNX2 expression. Cancer Res. 2010; 70(13):5577-86. PMC: 3037996. DOI: 10.1158/0008-5472.CAN-09-4602. View

Aldaz C, Ferguson B, Abba M . WWOX at the crossroads of cancer, metabolic syndrome related traits and CNS pathologies. Biochim Biophys Acta. 2014; 1846(1):188-200. PMC: 4151823. DOI: 10.1016/j.bbcan.2014.06.001. View

Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

Mirabello L, Troisi R, Savage S . Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer. 2009; 115(7):1531-43. PMC: 2813207. DOI: 10.1002/cncr.24121. View

Guttman M, Rinn J . Modular regulatory principles of large non-coding RNAs. Nature. 2012; 482(7385):339-46. PMC: 4197003. DOI: 10.1038/nature10887. View

10.

Kovac M, Blattmann C, Ribi S, Smida J, Mueller N, Engert F . Exome sequencing of osteosarcoma reveals mutation signatures reminiscent of BRCA deficiency. Nat Commun. 2015; 6:8940. PMC: 4686819. DOI: 10.1038/ncomms9940. View

11.

Ishibashi M, Kogo R, Shibata K, Sawada G, Takahashi Y, Kurashige J . Clinical significance of the expression of long non-coding RNA HOTAIR in primary hepatocellular carcinoma. Oncol Rep. 2013; 29(3):946-50. DOI: 10.3892/or.2012.2219. View

12.

Pluciennik E, Kusinska R, Potemski P, Kubiak R, Kordek R, Bednarek A . WWOX--the FRA16D cancer gene: expression correlation with breast cancer progression and prognosis. Eur J Surg Oncol. 2005; 32(2):153-7. DOI: 10.1016/j.ejso.2005.11.002. View

13.

Richards R . Fragile and unstable chromosomes in cancer: causes and consequences. Trends Genet. 2001; 17(6):339-45. DOI: 10.1016/s0168-9525(01)02303-4. View

14.

OLeary V, Ovsepian S, Carrascosa L, Buske F, Radulovic V, Niyazi M . PARTICLE, a Triplex-Forming Long ncRNA, Regulates Locus-Specific Methylation in Response to Low-Dose Irradiation. Cell Rep. 2015; 11(3):474-85. DOI: 10.1016/j.celrep.2015.03.043. View

15.

Brown J, Mitchell S, ONeill R . Making a long story short: noncoding RNAs and chromosome change. Heredity (Edinb). 2011; 108(1):42-9. PMC: 3238116. DOI: 10.1038/hdy.2011.104. View

16.

Rossi S, Sevignani C, Nnadi S, Siracusa L, Calin G . Cancer-associated genomic regions (CAGRs) and noncoding RNAs: bioinformatics and therapeutic implications. Mamm Genome. 2008; 19(7-8):526-40. DOI: 10.1007/s00335-008-9119-8. View

17.

Ottaviano L, Schaefer K, Gajewski M, Huckenbeck W, Baldus S, Rogel U . Molecular characterization of commonly used cell lines for bone tumor research: a trans-European EuroBoNet effort. Genes Chromosomes Cancer. 2009; 49(1):40-51. DOI: 10.1002/gcc.20717. View

18.

OLeary V, Smida J, Buske F, Carrascosa L, Azimzadeh O, Maugg D . PARTICLE triplexes cluster in the tumor suppressor WWOX and may extend throughout the human genome. Sci Rep. 2017; 7(1):7163. PMC: 5541130. DOI: 10.1038/s41598-017-07295-5. View

19.

Georgakilas A, Tsantoulis P, Kotsinas A, Michalopoulos I, Townsend P, Gorgoulis V . Are common fragile sites merely structural domains or highly organized "functional" units susceptible to oncogenic stress?. Cell Mol Life Sci. 2014; 71(23):4519-44. PMC: 4232749. DOI: 10.1007/s00018-014-1717-x. View

20.

Daw N, Billups C, Rodriguez-Galindo C, McCarville M, Rao B, Cain A . Metastatic osteosarcoma. Cancer. 2005; 106(2):403-12. DOI: 10.1002/cncr.21626. View